Mineralys Therapeutics, Inc.
MLYS
Jodie situation report
Mineralys Therapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 23 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 16 of 24 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as XNCR begins moving with the group.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Who this business touches
The relationships behind MLYS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MRKMerck & Company, Inc.partnerMar 12, 2026 ▾
“Our management team consists of industry veterans with extensive experience at pharmaceutical companies such as Merck, Novartis, ProQR, Sanifit, Teva, and Vertex.”
NVSNovartis AGpartnerMar 12, 2026 ▾
“Our management team consists of industry veterans with extensive experience at pharmaceutical companies such as Merck, Novartis, ProQR, Sanifit, Teva, and Vertex.”
PRQRFiling-linked namepartnerMar 12, 2026 ▾
“Our management team consists of industry veterans with extensive experience at pharmaceutical companies such as Merck, Novartis, ProQR, Sanifit, Teva, and Vertex.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MLYS is currently a Participant in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.